Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2010

View Archived Issues

Ramucirumab is tolerated in patients with advanced HCC in ongoing phase II trial

Almirall identifies new naphthyridine N-oxide as anti-inflammatory agent

Scientists reveal predictors of adverse events associated with losartan therapy for heart failure

Novel ACAT-1 inhibitors presented by Galderma

Scientists create Maraba MG1 virus strain with increased tumor-selective potency

NFL-10808 silences presynaptic serotonin 5-HT1A receptors and has antidepressant effects in vivo

Daiichi Sankyo identifies new inhibitors of HSP 90 ATPase activity

Ligand Pharmaceuticals and Proximagen collaborate on chemokine CXCR4 receptor target

Trial of TT-223/GLP-1 analogue combination in type 2 diabetes does not meet endpoints

RaQualia Pharma claims new motilin receptor agonists

Vantia identifies new vasopressin V1A receptor antagonists

LigoCyte begins phase I trial of bivalent intramuscular norovirus vaccine

Novel COX-1 inhibitors described by Japanese scientists

ImmunoCellular Therapeutics begins phase II glioblastoma study of ICT-107

Ablynx reports follow-up data from phase I study of ALX-0141

Faron Pharma advances FP-1201 into second part of trial in acute lung injury

Novartis Europharm withdraws Rasival MAA for essential hypertension

Phase III Northera trial meets endpoint in neurogenic orthostatic hypotension

Icagen suspends enrollment in photosensitivity study of ICA-105665

Boehringer Ingelheim begins phase III afatinib trial in breast cancer

EMA updates nevirapine label for patients with HIV-1 infection

Synvisc is approved in Japan for osteoarthritis of the knee

Hybrigenics reports phase IIa data on inecalcitol/docetaxel combination in prostate cancer

Endo Pharma completes tender offer for Penwest Pharma shares

SCH-527123 is safe and efficacious in phase II trial in COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...